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Introduction: Lymphedema is a potentially debilitating condition that occurs among breast cancer survivors.
This study examines the incidence of self-reported lymphedema, timing of lymphedema onset, and associations
between sociodemographic, clinical and lifestyle factors and lymphedema risk across racial-ethnic groups using data
from a multicenter, multiethnic prospective cohort study of breast cancer survivors, the Health, Eating, Activity and
Lifestyle Study.
Methods: A total of 666 women diagnosed with breast cancer staged as in situ, localized or regional disease at ages
35 to 64 years were recruited through the Surveillance, Epidemiology, and End Results registries in New Mexico
(non-Hispanic white and Hispanic white), Los Angeles County (black), and Western Washington (non-Hispanic
white) and followed for a median of 10.2 years. We evaluated sociodemographic factors, breast cancer- and
treatment-related factors, comorbidities, body mass index (BMI), hormonal factors, and lifestyle factors in relation
to self-reported lymphedema by fitting Cox proportional hazards models, estimating hazard ratios (HR) and 95%
confidence intervals (CI).
Results: Over the follow-up period, 190 women (29%) reported lymphedema. The median time from breast cancer
diagnosis to onset of lymphedema was 10.5 months (range: 0.5 to 134.9 months). Factors independently associated
with lymphedema were total/modified radical mastectomy (versus partial/less than total mastectomy; HR = 1.37, 95%
CI: 1.01 to 1.85), chemotherapy (versus no chemotherapy; HR = 1.48, 95% CI: 1.09 to 2.02), no lymph nodes removed
(versus ≥10 lymph nodes removed; HR = 0.17, 95% CI: 0.08 to 0.33), pre-diagnostic BMI ≥30 kg/m2 (versus BMI <25 kg/m2;
HR = 1.59, 95% CI: 1.09 to 2.31), and hypertension (versus no hypertension; HR = 1.49, 95% CI: 1.06 to 2.10). After
adjusting for demographics and breast cancer- and treatment-related factors, no significant difference in lymphedema
risk was observed across racial/ethnic groups. Analyses stratified by race/ethnicity showed that hypertension and
chemotherapy were lymphedema risk factors only for black women.
Conclusions: Breast cancer patients who have undergone extensive surgery or extensive lymph node dissection, or
who have a higher BMI should be closely monitored for detection and treatment of lymphedema. Further studies are
needed to understand the roles of chemotherapy and hypertension in the development of lymphedema.* Correspondence: lbernstein@coh.org
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Lymphedema is a relatively common and potentially de-
bilitating condition in which there is an excessive accumu-
lation of lymphatic fluid in the arm or hand. It develops
in approximately 20% of women after treatment for
breast cancer [1,2]; it can occur as a result of damage to
the lymphatic system from breast cancer treatment such
as axillary lymph node dissection or axillary radiother-
apy [3]. The use of sentinel lymph node biopsy, which
avoids unnecessary axillary lymph node surgery in pa-
tients with pathologically negative nodes, has reduced
the risk of lymphedema [4]; however, the risk of lymph-
edema has not been completely eliminated [5]. About
25% of patients who undergo sentinel lymph node biopsy
have positive nodes, for which patients undergo axillary
treatment [6]. Thus, many breast cancer patients remain
at risk of lymphedema.
Although lymphedema is not considered life threaten-
ing, its consequences include cosmetic deformity, physical
discomfort, and upper extremity disability [7]. Lymph-
edema also increases the risk of cellulitis, lymphangitis,
and occasionally lymphangiosarcoma [8-10]. No known
definitive cure for lymphedema is available and thus, af-
fected women live with lymphedema for many years.
Given the negative impact on quality of life [11-14] and
the potentially higher medical cost of managing lymph-
edema and treating lymphedema-induced conditions [8],
preventive measures are desired.
Many studies have evaluated a variety of demographic,
health, and clinical characteristics in relation to lymph-
edema [12,15-32]; however, the results vary widely, pos-
sibly due to differences in study design, statistical power,
analytic methods, measures used to define lymphedema,
demographic characteristics, or length of follow-up.
Furthermore, the majority of prior studies lacked racial/
ethnic diversity [18,19,22,28,29] or long-term follow-up
data [16-19,24,27,28,30-32]; data from long-term pro-
spective cohort studies in a diverse population remain
scarce. The Health, Eating, Activity, and Lifestyle (HEAL)
Study, has followed a cohort of breast cancer survivors for
more than 10 years and consists of non-Hispanic white
women, Hispanic women, and black women. Here, we as-
sess the incidence of self-reported lymphedema, timing of
lymphedema onset, and associations with breast cancer-
related and treatment-related factors, sociodemographic
factors, comorbidities, hormone-related factors, and life-
style factors across three racial/ethnic groups.
Materials and methods
Study setting, subjects, and recruitment
The aims, study design, and recruitment procedures of the
HEAL Study have been published previously [33,34].
Briefly, the HEAL Study is a multicenter, multiethnic pro-
spective breast cancer cohort study. Women diagnosedwith first primary in situ or Stage I to IIIA invasive breast
cancer between 1995 and 1999 were recruited into the
HEAL Study through the Surveillance, Epidemiology,
and End Results (SEER) registries in three regions of the
United States: New Mexico, Western Washington, and
Los Angeles County, California. The age ranges studied
varied by study site with women aged less than 92 years
recruited in New Mexico, women aged 40 to 65 years re-
cruited in Western Washington, and women aged 35 to
64 years recruited in Los Angeles County. A total of 1,183
women completed up to five assessments over 10 years
of follow-up. Four of those assessments were used for
this study. The first assessment (baseline assessment) was
administered in person within the first year (on average,
6 months) after a woman’s diagnosis (Figure 1). The sec-
ond assessment was administered, on average, 30 months
after a woman’s diagnosis (30-month assessment). The
30-month assessment was administered via in-person
interview or self-completed questionnaire. The third as-
sessment was administered, on average, 40 months after a
woman’s diagnosis (40-month assessment) by telephone
interview or mailed questionnaire in New Mexico, by
mailed questionnaire plus telephone follow-up in Western
Washington, and by telephone interview in Los Angeles
County. The last assessment was administered, on aver-
age, 123 months after a woman’s diagnosis (123-month as-
sessment) by telephone interview in New Mexico and Los
Angeles County and by mailed questionnaire or telephone
interview in Western Washington.
In the present study, we excluded 217 women who
were younger than 35 years (n = 4) or older than 64 years
(n = 213) in order to provide similar age distributions
across study sites. We also excluded 14 women who did
not receive any type of surgery; and 32 women whose
racial/ethnic classification was other than Hispanic
white, non-Hispanic white, or black, leaving 920 women.
A total of 751 (82%) of the 920 women completed the
30-month assessment. A total of 688 (92%) of the 751
women completed either the 40-month assessment or
the 123-month assessment (496 women completed both
the 40-month and the 123-month assessments, 163
women completed only the 40-month assessment, 29
women completed only the 123-month assessment). We
then excluded 22 women with incomplete or question-
able data on onset date of lymphedema (n = 12), number
of excised lymph nodes (n = 4), or body mass index
(BMI) (n = 6). The final analytic cohort consisted of 666
women; 666 (72%) of the eligible cohort had complete
data for this analysis (Figure 1).
We obtained informed consent from all participants
at each assessment. The study was approved by the insti-
tutional review boards at the University of Southern
California, University of New Mexico, Fred Hutchinson
Cancer Research Center, University of Louisville, and
Figure 1 Recruitment flow and data collection.
Togawa et al. Breast Cancer Research 2014, 16:414 Page 3 of 15
http://breast-cancer-research.com/content/16/1/414Beckman Research Institute of City of Hope in accord
with assurances filed with and approved by the U.S.
Department of Health and Human Services.
Data collection
Arm lymphedema
Participants provided information on lymphedema at the
40-month and 123-month assessments. To determine
the presence of lymphedema, we first presented our def-
inition of lymphedema to study participants: ‘Sometimes
the arm on the side on which you had breast cancer
becomes swollen because of an accumulation of fluid
in your arm. This is called lymphedema. Please do not
confuse this with the temporary swelling that occurs
after surgery’. We then asked the following ‘yes’ or ‘no’question: ‘Have you experienced lymphedema in your
arm at any time since your breast cancer diagnosis?’ For
women who answered ‘yes’, we also asked when they first
experienced lymphedema symptoms (month and year),
and whether they were still experiencing lymphedema at
the time of assessment. Lymphedema occurring within
one year of breast cancer diagnosis was considered
early-onset lymphedema, whereas that occurring more
than one year after diagnosis was considered late-onset
lymphedema.
Breast cancer-related and treatment-related factors
We obtained clinical data on diagnosis date, age at diagno-
sis, disease stage (SEER staging), treatment types (surger-
ies, radiation therapy, chemotherapy), tumor size, cancer
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cancer registry records and by abstracting participants’
hospital medical records. Tamoxifen use at or prior to
baseline was assessed using both hospital medical records
and self-report.
Sociodemographic and lifestyle factors
The baseline assessment captured sociodemographic infor-
mation such as race/ethnicity, marital status, educational
status, and insurance status. The baseline assessment
also captured information on history of smoking, alco-
hol intake in the year prior to diagnosis, and sports
and recreational physical activity in the year prior to
diagnosis. We calculated pack-years of smoking as the
number of packs of cigarettes per day times the number
of years the woman smoked, grams of alcohol con-
sumed per day, and metabolic equivalent task (MET)
hours of sports and recreational physical activity based
on the Compendium of Physical Activities compiled by
Ainsworth et al. [35].
Health-related and hormone-related factors
Information on comorbid medical conditions such as dia-
betes, hypertension, and arthritis, was collected through
self-report and hospital records. The number of women
having each condition and the proportion of women who
were identified in both sources, by self-report only and
by hospital records only, were as follows: hypertension -
198 women, 63%, 28%, 9% respectively; diabetes - 59
women, 53%, 32%, 15%, respectively; and arthritis - 186
women, 18%, 78%, 3%, respectively. Charlson Comorbidity
Index [36] was calculated based on data from hospital
medical records [37]. We did not count any carcinoma as
part of the Charlson Comorbidity Index. Participants also
reported information on height at age 18 years and weight
five years before diagnosis (black women in Los Angeles
County) or weight one year before diagnosis (Hispanic
women in New Mexico and non-Hispanic white women
in New Mexico and Western Washington) at the baseline
assessment. BMI prior to diagnosis was calculated as
weight (kg) divided by the square of height (m2). The
baseline assessment also captured information on oral
contraceptive use and postmenopausal hormone replace-
ment therapy use before breast cancer diagnosis, and
menopausal status at diagnosis. Menopausal status was
determined based on the following questionnaire data:
age, date of last menstruation, and hysterectomy and oo-
phorectomy status [38].
Statistical analysis
Descriptive statistics by race/ethnicity were obtained for
breast cancer-related and treatment-related factors,
sociodemographic factors, health-related factors, hormo-
nal factors, and lifestyle factors (Table S1 in Additionalfile 1). Time to onset of lymphedema was calculated as
the time from breast cancer diagnosis until self-reported
first lymphedema occurrence; we used these data to gen-
erate a cumulative incidence curve (Figure 2).
To identify factors associated with self-reported lymph-
edema, we fit Cox proportional hazards models and ob-
tained estimates of the hazard ratio (HR) and its 95%
confidence interval (CI) using time since diagnosis as the
time scale [39]. Women were followed from date of breast
cancer diagnosis to date of first lymphedema occurrence
or until date of last follow-up. One hundred fifty-six
women who died or were lost to follow-up between the
40-month and the 123-month assessments contributed
follow-up only through the 40-month assessment because
their lymphedema status after the 40-month assessment
was unknown. We considered the following variables as
potential covariates in our multivariate models: breast
cancer disease stage (in situ, localized, regional), tumor
size (smaller than 10, 10 to 19, 20 mm or greater, missing),
tumor location (nipple/central portion or upper/lower
inner quadrant, upper/lower outer quadrant, overlapping
lesion, axillary tail or not specified), surgery type (partial
or less than total mastectomy or unspecified surgery, total
or modified radical mastectomy), reconstructive surgery
(yes, no), number of excised lymph nodes (0, 1 to 9, 10 or
more), radiation therapy (yes, no), chemotherapy (yes, no),
tamoxifen (yes, no), marital status (married, widowed, di-
vorced or separated, never married), education status
(high school or less, some college, college degree, graduate
studies), medical insurance (yes, no), BMI prior to diagno-
sis (less than 25 (underweight or normal), 25 to 29.9 (over-
weight), and 30 kg/m2 or above (obese)), menopausal
status at diagnosis (premenopausal, postmenopausal, un-
known), hypertension at or prior to diagnosis (yes, no),
diabetes at or prior to diagnosis (yes, no), arthritis at or
prior to diagnosis (yes, no), and Charlson Comorbidity
Index (0, 1 to 2), oral contraceptive use prior to diagnosis
(yes, no), estrogen use prior to diagnosis (yes, no, missing),
progestin use prior to diagnosis (yes, no, missing), pack-
years of smoking (less than 0.05, 0.05 to 5.3, 5.4 to 20.5,
more than 20.5), alcohol intake in the year prior to diag-
nosis (less than 1, 1 to 6, more than 6 grams per day),
physical activity during the year prior to diagnosis (less
than 0.5, 0.5 to 20, more than 20 MET hours per week).
Age at diagnosis (35 to 44, 45 to 49, 50 to 54, 55 to 59, 60
to 64 years) and race/ethnicity (non-Hispanic white
(Western Washington, New Mexico), black (Los Angeles
County), Hispanic white (New Mexico)) were considered
design variables and were included in all models.
Each variable was added to an age- and race/ethnicity-
adjusted model and a likelihood ratio test was performed
to test whether the variable significantly improved the
model fit. Postmenopausal estrogen use and progestin
use were examined among postmenopausal women only.
Figure 2 Kaplan-Meier cumulative incidence estimate of self-reported arm lymphedema.
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status, age was treated as continuous. All variables with
a P value less than 0.05 based on the likelihood ratio test
were then added to an age- and race/ethnicity-adjusted
model one at a time in order from the variable with the
smallest P value to the variable with largest P value to
examine whether the addition of each variable improved
the fit of the model. Only the variables that significantly
improved the model were kept in the final model. The
final multivariable model included race/ethnicity, age at
diagnosis, surgery type, number of excised lymph nodes,
chemotherapy, BMI and hypertension. We also tested
for exposure-associated trends in risk of lymphedema
for variables represented by ordinal values by fitting the
original values in our model and testing whether the co-
efficient associated with that covariate differed from
zero. In addition, we tested interactions between vari-
ables included in the final multivariable model by creat-
ing an interaction term and using a likelihood ratio test.
We considered a two-sided P value less than 0.05 as sta-
tistically significant.
In exploratory analyses, we evaluated whether the asso-
ciation with lymphedema for each of the variables in the
final multivariable model differed by timing of lymph-
edema onset; to do this, we created an interaction term
using a time-dependent indicator for follow-up (12 months
or less, longer than 12 months). We then performed a
likelihood ratio test to compare the interaction model to
the model without the interaction term. We also assessed
the association of each risk factor with the development of
lymphedema within each racial/ethnic group.
Finally, we performed sensitivity analyses by excluding
women with in situ breast cancer and reevaluating thefinal multivariable model; we also reran analyses censoring
women who developed a recurrence or new primary
breast cancer at the time of these events.
All analyses were performed using the STATA software
(Version 12; StataCorp LP, College Station, TX, USA).
Results
Characteristics of study population
The study population consisted of three racial/ethnic
groups: 371 non-Hispanic white women (n = 225 (New
Mexico), n = 146 (Western Washington)), 226 black women
(Los Angeles County), and 69 Hispanic women (New
Mexico). Participant characteristics by race/ethnicity are
shown in Table S1 in Additional file 1. The mean age at
breast cancer diagnosis was 51.5 years (standard devi-
ation = 7.2). Approximately 23% of the participants had
in situ breast cancer, 52% had localized disease, and
25% had regional disease. Prior to breast cancer diag-
nosis, approximately 33% of the women were over-
weight (BMI = 25.0 to 29.9 kg/m2) and 21% were obese
(BMI ≥30 kg/m2).
The median length of follow-up since breast cancer diag-
nosis was 10.2 years (range: 2.4 to 12.4 years). During
follow-up, 190 women (29%) reported lymphedema. The
median time from breast cancer diagnosis to onset of
lymphedema was 10.5 months (range: 0.5 to 134.9 months).
The cumulative incidence of lymphedema was 15.8%,
20.9%, 26.1%, and 29.7%, at 1, 2, 5, and 10 year(s), respect-
ively (Figure 2). One hundred nine (77%) of 141 women
who reported lymphedema at the 40-month assessment
completed the 123-month assessment. Among these 109
women, 63 (58%) women indicated that their lymphedema
was still present at the time of the 123-month assessment.
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We present a series of hazard ratios for individual factors
considered as potential risk factors for lymphedema in
Table 1. When age at diagnosis and race/ethnicity were
mutually adjusted, the oldest age group (60 to 64 years)
had a lower risk of lymphedema than the youngest age
group (35 to 44 years) (HR = 0.59, 95% CI: 0.35 to 0.97)
and black women had a higher risk of lymphedema than
non-Hispanic white women (HR = 1.62, 95% CI: 1.20 to
2.20). Women with in situ breast cancer had a substan-
tially lower risk of lymphedema than women with local-
ized breast cancer after adjusting for age at diagnosis
and race/ethnicity (HR = 0.26, 95% CI: 0.15 to 0.45).
Women with regional breast cancer were more likely to
develop lymphedema than women with localized breast
cancer; however the 95% CI included 1.0 (HR = 1.35,
95% CI: 0.99 to 1.85). We excluded disease stage from
the final model since disease stage was strongly associ-
ated with treatment-related factors. In addition to dis-
ease stage, the following variables added significantly to
the age- and race/ethnicity-adjusted model based on
likelihood ratio test (P <0.05): tumor size, surgery type,
number of excised lymph nodes, chemotherapy, tamoxi-
fen, BMI, and hypertension. No statistically significant
association was observed for other factors.
Multivariable analyses overall
Tumor size and tamoxifen did not significantly improve
the model fit once number of excised lymph nodes was
in the model, and thus these variables were not included
in the final multivariable model. The final model in-
cluded age at diagnosis, race/ethnicity, surgery type, num-
ber of excised lymph nodes, chemotherapy, BMI, and
hypertension. In this multivariable model, the 95% CI
for black women no longer excluded one (versus non-
Hispanic white women; HR = 1.16, 95% CI: 0.83 to 1.61).
Treatment-related factors including total or modified rad-
ical mastectomy (versus partial or less than total mast-
ectomy; HR = 1.37, 95% CI: 1.01 to 1.85), no lymph
nodes removed (versus 10 or more excised lymph nodes;
HR = 0.17, 95% CI: 0.08 to 0.33), and chemotherapy
(HR = 1.48, 95% CI: 1.09 to 2.02) were associated with
the risk of lymphedema. The risk of developing lymph-
edema increased by 5% for each lymph node removed
(P trend <0.001). Among the health-related factors, hav-
ing BMI ≥30 kg/m2 (versus BMI <25 kg/m2; HR = 1.59,
95% CI: 1.09 to 2.31) and having hypertension (HR =
1.49, 95% CI: 1.06 to 2.10) were associated with in-
creased lymphedema risk. We observed a statistically
significant increasing trend in risk with increasing BMI
(P trend = 0.01). None of the prediagnosis lifestyle factors
had a substantial effect on the risk of lymphedema. The
results from the multivariable analyses were not meaning-
fully changed when we performed sensitivity analyses inwhich we excluded women with in situ breast cancer or
when we reran analyses censoring women who developed
a recurrence or new primary breast cancer at the time of
these events.
Multivariable analyses by timing of lymphedema onset
Women’s characteristics and their associations with
early-onset and late-onset lymphedema are presented in
Table 2. Older age was associated with decreased risk of
late-onset lymphedema (P trend = 0.002), but not with
early-onset lymphedema (P trend = 0.91). The risk of
late-onset lymphedema decreased by 5% per year in-
crease in age (HR = 0.95, 95% CI: 0.92 to 0.98). We ob-
served a statistically significant difference in the age
effect between early- and late-onset lymphedema when
age was treated as continuous (P = 0.02). Our results also
showed that the risk of both early-onset and late-onset
lymphedema increased with increasing number of ex-
cised lymph nodes (HR = 1.04, 95% CI: 1.01 to 1.06;
HR = 1.06, 95% CI: 1.03 to 1.09; respectively). The influ-
ence of chemotherapy on risk for late-onset lymphedema
(HR = 1.77, 95% CI: 1.13 to 2.78) was greater than the ef-
fect of chemotherapy on risk for early-onset lymph-
edema (HR = 1.28, 95% CI: 0.86 to 1.91); however, these
two hazard ratios did not differ statistically (P = 0.27).
Multivariable analyses stratified by race/ethnicity
The results showed that the associations of chemotherapy
and hypertension with the risk of developing lymphedema
varied across racial/ethnic groups (P = 0.01, P <0.001, re-
spectively) (Table 3); both receipt of chemotherapy and
hypertension were associated with an elevated risk of
lymphedema among black women only (HR = 2.69, 95%
CI: 1.61 to 4.50; HR = 2.73, 95% CI: 1.65 to 4.53; respect-
ively). The associations of age at breast cancer diagnosis
and surgery type with the risk of lymphedema also ap-
peared to vary across the racial/ethnic groups, but no sta-
tistically significant interactions by race/ethnicity were
detected (Table 3).
Discussion
This prospective cohort study of women diagnosed with
first primary in situ or Stage I to IIIA invasive breast
cancer between the ages of 35 and 64 years supports
previous findings that the risk of lymphedema is higher
among women who had more lymph nodes removed,
more extensive surgery, and higher BMI. This study also
highlights the importance of long-term monitoring of
breast cancer survivors, particularly those who are youn-
ger, have had more lymph nodes removed, or received
chemotherapy, as they are at a higher risk of developing
late-onset lymphedema.
This study demonstrates that the cumulative incidence
of lymphedema increases with time and that lymphedema
Table 1 Participant characteristics and their associations with lymphedema among 666 female breast cancer survivors
Characteristics Categories N at risk LE (%) HR (95% CI)a HR (95% CI)b
Breast cancer and treatment
Age at diagnosis (years) 35-44 123 43 (35.0) 1.00 1.00
45-49 128 43 (33.6) 0.98 (0.64 - 1.50) 0.98 (0.63 - 1.52)
50-54 175 46 (26.3) 0.80 (0.52 - 1.21) 0.79 (0.51 - 1.23)
55-59 128 35 (27.3) 0.83 (0.53 - 1.30) 0.78 (0.49 - 1.23)
60-64 112 23 (20.5) 0.59 (0.35 - 0.97) 0.61 (0.35 - 1.06)
Per unit of age 0.98 (0.96 - 1.00) 0.98 (0.96 - 1.00)
P trend = 0.03 P trend = 0.04
Disease stage In situ 155 15 (9.7) 0.26 (0.15 - 0.45)
Localized 346 105 (30.4) 1.00
Regional 165 70 (42.4) 1.35 (0.99 - 1.85)
Tumor size (mm) <10 178 36 (20.2) 1.00
10-19 216 66 (30.6) 1.54 (1.02 - 2.32)
20+ 208 76 (36.5) 1.85 (1.23 - 2.77)
Missing 64 12 (18.8) 0.80 (0.41 - 1.54)
Per mm 1.01 (1.00 - 1.02)
P trend = 0.02
Cancer location Nipple, central portion, upper/lower
inner quadrant
143 44 (30.8) 1.15 (0.80 - 1.66)
Upper/lower outer quadrant 292 83 (28.4) 1.00
Overlapping lesion 147 44 (29.9) 1.07 (0.74 - 1.55)
Axillary tail, NOS 84 19 (22.6) 0.75 (0.46 - 1.24)
Surgery type Partial/less than total mastectomy/
surgery, NOS
442 108 (24.4) 1.00 1.00
Total mastectomy/modified radical
mastectomy
224 82 (36.6) 1.52 (1.13 - 2.04) 1.37 (1.01 - 1.85)
Reconstructive surgery No 533 150 (28.1) 1.00
Yes 105 33 (31.4) 0.98 (0.67 - 1.45)
Missing 28 7 (25.0) -
Number of excised lymph nodes 0 143 9 (6.3) 0.13 (0.06 - 0.25) 0.17 (0.08 - 0.33)
1-9c 162 32 (19.8) 0.44 (0.30 - 0.64) 0.46 (0.31 - 0.68)
10+ 361 149 (41.3) 1.00 1.00
Per lymph node 1.06 (1.04 - 1.08) 1.05 (1.03 - 1.07)
P trend <0.001 P trend < 0.001
Radiation No 270 73 (27.0) 1.00
Yes 396 117 (29.6) 1.21 (0.90 - 1.63)
Chemotherapy No 413 83 (20.1) 1.00 1.00
Yes 253 107 (42.3) 2.28 (1.69 - 3.09) 1.48 (1.09 - 2.02)
Tamoxifen No 382 96 (25.1) 1.00
Yes 284 94 (33.1) 1.58 (1.18 - 2.12)
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Table 1 Participant characteristics and their associations with lymphedema among 666 female breast cancer survivors
(Continued)
Sociodemographic factors
Race/ethnicity Non-Hispanic white (NM, WW) 371 88 (23.7) 1.00 1.00
Black (LA) 226 82 (36.3) 1.62 (1.20 - 2.20) 1.16 (0.83 - 1.61)
Hispanic white (NM) 69 20 (29.0) 1.19 (0.73 - 1.94) 1.04 (0.63 - 1.70)
Marital status Married 445 123 (27.6) 1.00
Widowed 34 10 (29.4) 1.25 (0.64 - 2.43)
Divorced/separated 140 46 (32.9) 1.20 (0.86 - 1.69)
Never married 47 11 (23.4) 0.85 (0.45 - 1.58)
Education High school or less 158 48 (30.4) 1.00
Some college 249 75 (30.1) 0.92 (0.63 - 1.33)
College graduate 120 39 (32.5) 1.14 (0.73 - 1.77)
Graduate studies 139 28 (20.1) 0.65 (0.40 - 1.07)
Insurance Yes 618 180 (29.1) 1.00
No 25 8 (32.0) 1.04 (0.51 - 2.12)
Missing 23 2 (8.7) -
Health-related factors
Body mass index prior to diagnosis
(kg/m2)
<25 306 70 (22.9) 1.00 1.00
25-29.9 220 67 (30.5) 1.40 (0.99 - 1.96) 1.25 (0.88 - 1.76)
30+ 140 53 (37.9) 1.83 (1.27 - 2.63) 1.59 (1.09 - 2.31)
Per unit of BMI 1.04 (1.02 - 1.07) 1.04 (1.01 - 1.06)
P trend < 0.001 P trend = 0.01
Menopausal statusd Premenopausal 259 82 (31.7) 1.00
Postmenopausal 341 80 (23.5) 0.81 (0.51 - 1.28)
Unknown 66 28 (42.4) 1.44 (0.91 - 2.26)
Hypertension No 468 122 (26.1) 1.00 1.00
Yes 198 68 (34.3) 1.54 (1.11 - 2.12) 1.49 (1.06 - 2.10)
Diabetes No 607 174 (28.7) 1.00
Yes 59 16 (27.1) 0.96 (0.57 - 1.62)
Arthritis No 480 135 (28.1) 1.00
Yes 186 55 (29.6) 1.19 (0.86 - 1.65)
Charlson Comorbidity Index 0 599 177 (29.6) 1.00
1-2 65 13 (20.0) 0.70 (0.40 - 1.24)
Missing 2 0 (0.0) -
Hormonal factors
Oral contraceptives use prior to diagnosis No 189 48 (25.4) 1.00
Yes 477 142 (29.8) 1.12 (0.79 - 1.58)
Estrogen use prior to diagnosisd,e No 120 26 (21.7) 1.00
Yes 210 52 (24.8) 1.36 (0.83 - 2.24)
Missing 11 2 (18.2) -
Progestin use prior to diagnosisd,e No 205 52 (25.4) 1.00
Yes 119 23 (19.3) 0.94 (0.56 - 1.59)
Missing 17 5 (29.4) -
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Table 1 Participant characteristics and their associations with lymphedema among 666 female breast cancer survivors
(Continued)
Lifestyle factors
Pack-years of smoking <100 cigarettes in lifetime, <0.05
pack-years
326 92 (28.2) 1.00
0.05-5.3 pack-years 112 33 (29.5) 1.06 (0.71 - 1.58)
5.4-20.5 pack-years 111 37 (33.3) 1.31 (0.89 - 1.93)
>20.5 pack-years 114 27 (23.7) 0.93 (0.60 - 1.44)
Missing 3 1 (33.3) -
Per pack-year of smoking 1.00 (0.99 - 1.01)
P trend = 0.47
Alcohol intake year prior to diagnosis
(grams per day)
<1 329 102 (31.0) 1.00
1-6 99 25 (25.3) 0.82 (0.52 - 1.28)
>6 117 29 (24.8) 0.94 (0.61 - 1.45)
Missing 121 34 (28.1) 1.28 (0.79 - 2.09)
Per gram of alcohol 0.99 (0.97 - 1.01)
P trend = 0.42
Sports and recreational activities year
prior to diagnosis (MET hours/week)
<0.5 223 68 (30.5) 1.00
0.5-20.0 298 85 (28.5) 1.13 (0.80 - 1.59)
>20.0 144 37 (25.7) 1.09 (0.71 - 1.67)
Missing 1 0 (0.0) -
Per MET hour 1.00 (0.99 - 1.01)
P trend = 0.80
aHR is adjusted for race/ethnicity (non-Hispanic white (New Mexico), non-Hispanic white (Western Washington), black (Los Angeles), Hispanic (New Mexico)) and
age at diagnosis (35-44, 45-49, 50-54, 55-59, 60-64). Age is adjusted for only race/ethnicity. Race/ethnicity is adjusted for only age. bCox proportional hazard model
includes age, race/ethnicity, surgery type, number of excised lymph nodes, chemotherapy, BMI, and hypertension. c‘1 to 9’ category includes ‘at least one lymph
node removed’. dAge in years (35 to 64) was used to adjust for the age effect. eOnly postmenopausal women were included. N, number; LE, lymphedema; HR,
hazard ratio; CI, confidence interval; NOS, not otherwise specified; NM, New Mexico; WW, Western Washington; LA, Los Angeles County; BMI, body mass index;
MET, metabolic equivalent task.
Togawa et al. Breast Cancer Research 2014, 16:414 Page 9 of 15
http://breast-cancer-research.com/content/16/1/414can develop later in the survival trajectory. Although many
studies have reported incidence of lymphedema, compari-
son across studies is difficult because of variability in
lymphedema definition and assessment, length of follow-
up, and associated patient characteristics. In a study con-
ducted by Kwan and colleagues [17] where length of
follow-up for each participant was considered to calculate
cumulative incidence of lymphedema, the cumulative inci-
dence of lymphedema was 10.4% at one year and 13.5% at
two years after breast cancer diagnosis. These cumulative
incidence values were lower than those observed in our
study, perhaps because their participants were diagnosed
with breast cancer more recently when sentinel lymph
node biopsy was more common than it was when partici-
pants in the HEAL Study were diagnosed. Also, the study
by Kwan et al. required hospital records to establish the
presence of lymphedema.
The existing data on whether lymphedema incidence
varies by age have been inconsistent. Contrary to some
of the previous studies [16,18] and despite the limited
age range in our study (35 to 64 years), we found that
older women were less likely to develop lymphedemathan younger women. We observed a statistically signifi-
cant, decreasing linear trend in lymphedema risk associ-
ated with increasing age after adjusting for breast cancer
characteristics and treatment factors, hypertension, and
BMI (P = 0.04). Our results for age are consistent with
those from other studies [19,29,40]. When we examined
the effects of age by timing of onset, we found that age
was inversely associated with risk of late-onset lymph-
edema, but not with risk of early-onset lymphedema.
The age-by-time interaction was statistically significant
when age was treated as continuous (P = 0.02). The rea-
son why older women are less likely to develop lymph-
edema later in the survival trajectory is unclear. A
previous study showed that infection or injury was asso-
ciated with increased risk of late-onset lymphedema
[20]. We were unable to adjust for the effect of infection
or injury. Thus we cannot rule out the possibility of re-
sidual confounding. More research is needed to study
the age effect on late-onset lymphedema.
This study identified two modifiable risk factors for
lymphedema. One of the modifiable risk factors was pre-
diagnosis BMI; women with higher prediagnosis BMI
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http://breast-cancer-research.com/content/16/1/414were at a higher risk of lymphedema. The association
between prediagnosis BMI and risk of lymphedema has
been shown in the Iowa Women’s Health Study [22] and
another study conducted by Jammallo et al. [32]. Other
studies have found an association between at-diagnosis
or post-diagnosis BMI and the risk of lymphedema
[15,23,24,28]. The mechanism by which excess weight
increases the risk of lymphedema remains unclear; the
risk of lymphedema may be elevated in obese women
due to additional demand on both the vascular and
lymphatic systems to transport fluid [28]. Weight gain
during survivorship in relation to lymphedema risk is
also of interest. Petrek et al. [20] reported an association
between weight gain since operation and risk of breast
cancer-related lymphedema. However, our study failed
to demonstrate an association between change in BMI
(BMI at 30-month assessment minus prediagnosis BMI)
and late-onset lymphedema (data not shown). More
studies are needed to understand the association be-
tween BMI and the risk of lymphedema.
The other modifiable risk factor we found in the
present study was hypertension. We found that hyper-
tension was associated with increased risk of lymph-
edema after adjusting for BMI, which contradicts some
studies where no association between hypertension and
lymphedema was found [21-23,27]. A possible mechan-
ism by which hypertension increases the risk is through
increased capillary filtration due to elevated hydrostatic
pressure. When capillary filtration increases and lymph-
atic drainage is insufficient, the fluid accumulates in
interstitial space leading to swelling of the arm. Our data
indicated that the risk of lymphedema among women
with hypertension, relative to women without hyperten-
sion, was not altered substantially after adjusting for an-
tihypertensive medication use (HR = 1.58, 95% CI: 1.05
to 2.37). We also examined potential confounding effects
of different types of antihypertensive medications such
as vasodilators, calcium blockers, beta blockers, alpha
blockers, angiotensin-converting enzyme, and diuretics.
Among these medications, only the use of diuretics sub-
stantially decreased the HR associated with hyperten-
sion; the 95% CI included one after adjusting for
diuretics use (HR = 1.40, 95% CI: 0.96 to 2.03). Our
study also showed that hypertension increased the risk
of lymphedema among black women, but not other
women. Since black women with hypertension were
more likely to take diuretics than non-black women with
hypertension in our study (P = 0.02), the observed inter-
action by race/ethnicity could possibly be explained by
the association between use of diuretics and the risk of
lymphedema. However, among women with hyperten-
sion, we found no significant association between diur-
etic use and lymphedema (treatment with diuretics
versus no treatment with diuretics; HR = 1.04, 95% CI:0.61 to 1.78). Similarly, we found no significant associ-
ation between diuretic use and lymphedema among
black women with hypertension (treatment with di-
uretics versus no treatment with diuretics; HR = 1.06,
95% CI: 0.56 to 2.00). These findings do not support the
hypothesis that the interaction between hypertension
and race is due to the more frequent use of diuretics
among black women. Due to lack of information on dur-
ation, timing, and rationale for selecting a particular type
of antihypertensive medication in this study, the associ-
ation between antihypertensive medications and lymph-
edema risk needs further clarification in future studies.
Our study results agree with the majority of studies
showing that lymphedema risk increases with increasing
number of excised lymph nodes [12,17,22,25]. This posi-
tive association between number of excised lymph nodes
and risk remained significant after restricting the cohort
to women with invasive breast cancer (P trend = 0.002).
On the other hand, our study failed to confirm an associ-
ation with radiation therapy. We also did not observe ef-
fect modification of radiation therapy by number of
excised lymph nodes (P = 0.18). However, detailed infor-
mation on location, dose, and duration of radiation ther-
apy was not available in this study. Since the risk of
lymphedema depends on the type of radiotherapy [41], we
may have missed an association with radiation treatment.
Evidence on associations between chemotherapy and
lymphedema risk has been inconsistent, with some studies
finding a positive association [8,12,17,19,22,23] and others
finding no association [16,25-27,29]. The present study
showed a positive association between chemotherapy and
overall lymphedema risk after adjusting for other risk fac-
tors (HR = 1.48, 95% CI: 1.09 to 2.02). This association
persisted after excluding women with in situ breast cancer
(HR = 1.47, 95% CI: 1.06 to 2.03). When we examined in-
dividual types of chemotherapy adjusting for other risk
factors, we found that 5-fluorouracil, methotrexate, and
cyclophosphamide were associated with increased risk of
lymphedema whereas taxane and doxorubicin were not.
Women who received 5-fluorouracil, methotrexate, and
cyclophosphamide in combination may have a higher risk
of infection because these agents together tend to reduce
the number of white blood cells and compromise immune
response [42]. It is conceivable that the elevated lymph-
edema risk observed in women who received these
chemotherapy agents may be partly attributable to infec-
tion. Our exploratory analysis further demonstrated a sta-
tistically significant interaction between chemotherapy
and hypertension in relation to lymphedema risk among
women diagnosed with invasive breast cancer. More
specifically, the risk of lymphedema was elevated only
among women with hypertension who received chemo-
therapy (versus women without hypertension who did
not receive chemotherapy; HR = 2.36, 95% CI: 1.54 to
Table 2 Participant characteristics and their associations with early-onset and late-onset lymphedema










Breast cancer and treatment
Age at diagnosis (years) 35-44 18/123 25/105 1.00 1.00
45-49 22/128 21/106 1.19 (0.63 - 2.24) 0.83 (0.46 - 1.51)
50-54 29/175 17/146 1.19 (0.65 - 2.17) 0.51 (0.27 - 0.96)
55-59 20/128 15/108 1.04 (0.54 - 2.00) 0.59 (0.31 - 1.12)
60-64 16/112 7/96 1.03 (0.50 - 2.10) 0.31 (0.13 - 0.74) 0.15
Per unit of age 1.00 (0.97 - 1.03) 0.95 (0.92 - 0.98) 0.02
P trend = 0.91 P trend = 0.002
Surgery type Partial/less than total mastectomy/
surgery, NOS
57/442 51/385 1.00 1.00
Total mastectomy/modified radical
mastectomy
48/224 34/176 1.41 (0.95 - 2.09) 1.32 (0.84 - 2.06) 0.82
Number of excised lymph nodes 0 5/143 4/138 0.20 (0.08 - 0.51) 0.13 (0.05 - 0.37)
1-9c 19/162 13/143 0.57 (0.34 - 0.95) 0.36 (0.20 - 0.65)
10+ 81/361 68/280 1.00 1.00 0.44
Per lymph node 1.04 (1.01 - 1.06) 1.06 (1.03 - 1.09) 0.20
P trend = 0.003 P trend <0.001
Chemotherapy No 47/413 36/366 1.00 1.00
Yes 58/253 49/195 1.28 (0.86 - 1.91) 1.77 (1.13 - 2.78) 0.27
Sociodemographic factors
Race/ethnicity Non-Hispanic white (NM, WW) 50/371 38/321 1.00 1.00
Black (LA) 45/226 37/181 1.08 (0.70 - 1.65) 1.26 (0.79 - 2.02)
Hispanic white (NM) 10/69 10/59 0.90 (0.45 - 1.78) 1.24 (0.61 - 2.50) 0.77
Health-related factors
Body mass index prior to diagnosis
(kg/m2)
<25 37/306 33/269 1.00 1.00
25-29.9 36/220 31/184 1.24 (0.78 - 1.98) 1.25 (0.76 - 2.06)
30+ 32/140 21/108 1.64 (1.00 - 2.67) 1.52 (0.87 - 2.66) 0.97
Per unit of BMI 1.03 (1.00 - 1.07) 1.04 (1.00 - 1.08) 0.91
P trend = 0.05 P trend = 0.07
Hypertension No 63/468 59/405 1.00 1.00
Yes 42/198 26/156 1.65 (1.08 - 2.54) 1.30 (0.80 - 2.13) 0.44
aHR is adjusted for all the other variables in the table. bP value for interaction between a characteristic and timing of lymphedema onset (early versus late) is
derived from a likelihood ratio test. c‘1 to 9’ category includes ‘at least one lymph node removed’. LE, lymphedema; HR, hazard ratio; CI, confidence interval; NOS,
not otherwise specified; NM, New Mexico; WW, Western Washington; LA, Los Angeles County; BMI, body mass index.
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http://breast-cancer-research.com/content/16/1/4143.64). Swystun and colleagues [43] suggested that the
chemotherapy metabolite acrolein may upregulate pro-
coagulant pathways, while impairing endogenous anti-
coagulant pathways. In our study, 222 (88%) of 253
women treated with chemotherapy received cyclophos-
phamide, which has been associated with an increased
risk of thrombosis [43-45]. It is possible that this pro-
coagulant activity might overburden the lymphatic sys-
tem in women with preexisting hypertension.
Although lymphedema among breast cancer survivors
has been studied extensively, data from studies with long-
term follow-up of ethnically diverse populations remainscarce. Kwan et al. [17] found that black women had a
higher risk of lymphedema compared to white women
whereas Meeske et al. [2] found no association between
race (black versus non-Hispanic white) and lymphedema
risk after adjusting for other risk factors. Note that the
black women in the study by Meeske et al. [2] are the
same black women who are included in this report, but
follow-up for lymphedema was limited to the 40-month
assessment in their study. With follow-up extended through
the 123-month assessment, we observed that the elevated
lymphedema risk among black women was attenuated
after adjusting for age, treatment-related factors, BMI, and
Table 3 Risk factors for arm lymphedema stratified by race/ethnicity
Non-Hispanic white Black Hispanic white
Characteristics Categories N LE (%) HR (95% CI)a N LE (%) HR (95% CI)a N LE (%) HR (95% CI)a P for interactionb
Age at diagnosis (years) 35-44 56 19 (33.9) 1.00 53 21 (39.6) 1.00 14 3 (21.4) 1.00
45-49 65 16 (24.6) 0.90 (0.45 - 1.77) 46 20 (43.5) 1.00 (0.53 - 1.92) 17 7 (41.2) 2.23 (0.50 - 10.07)
50-54 112 28 (25.0) 0.77 (0.42 - 1.40) 48 17 (35.4) 0.87 (0.44 - 1.72) 15 1 (6.7) 0.40 (0.04 - 4.30)
55-59 77 17 (22.1) 0.74 (0.38 - 1.44) 37 13 (35.1) 0.69 (0.33 - 1.44) 14 5 (35.7) 2.77 (0.56 - 13.77)
60-64 61 8 (13.1) 0.42 (0.17 - 1.00) 42 11 (26.2) 0.60 (0.26 - 1.34) 9 4 (44.4) 9.17 (1.43 - 58.94) 0.24
Surgery type Partial/less than total mastectomy/
surgery, NOS
272 53 (19.5) 1.00 123 43 (35.0) 1.00 47 12 (25.5) 1.00
Total/modified radical mastectomy 99 35 (35.4) 1.58 (1.02 - 2.45) 103 39 (37.9) 1.15 (0.72 - 1.81) 22 8 (36.4) 2.16 (0.71 - 6.54) 0.39
Number of excised lymph nodes 0 88 3 (3.4) 0.10 (0.03 - 0.32) 41 5 (12.2) 0.41 (0.16 - 1.10) 14 1 (7.1) 0.09 (0.01 - 0.80)
1-9c 100 18 (18.0) 0.48 (0.28 - 0.82) 49 13 (26.5) 0.64 (0.35 - 1.18) 13 1 (7.7) 0.09 (0.01 - 0.70)
10+ 183 67 (36.6) 1.00 136 64 (47.1) 1.00 42 18 (42.9) 1.00 0.48
Chemotherapy No 250 43 (17.2) 1.00 124 27 (21.8) 1.00 39 13 (33.3) 1.00
Yes 121 45 (37.2) 1.25 (0.80 - 1.95) 102 55 (53.9) 2.69 (1.61 - 4.50) 30 7 (23.3) 0.69 (0.24 - 2.03) 0.01
Body mass index (kg/m2) <25 192 42 (21.9) 1.00 89 23 (25.8) 1.00 25 5 (20.0) 1.00
25-29.9 114 26 (22.8) 1.05 (0.64 - 1.73) 76 32 (42.1) 1.58 (0.90 - 2.78) 30 9 (30.0) 2.25 (0.65 - 7.72)
30+ 65 20 (30.8) 1.50 (0.86 - 2.61) 61 27 (44.3) 1.65 (0.91 - 2.98) 14 6 (42.9) 3.94 (0.99 - 15.75) 0.46
Hypertension No 292 73 (25.0) 1.00 119 30 (25.2) 1.00 57 19 (33.3) 1.00
Yes 79 15 (19.0) 0.95 (0.52 - 1.74) 107 52 (48.6) 2.73 (1.65 - 4.53) 12 1 (8.3) 0.21 (0.02 - 2.00) <0.001
aRace/ethnicity-specific HR is adjusted for all of the other variables in this table. bP value for interaction between a characteristic and race/ethnicity is derived from a likelihood ratio test. c‘1 to 9’ category includes ‘at
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1.16, 95% CI: 0.83 to 1.61). Our exploratory analysis exam-
ining racial/ethnic-specific associations showed that chemo-
therapy and hypertension were lymphedema risk factors
only among black breast cancer survivors; thus, the ob-
served overall effects of these factors on lymphedema risk
appear to be limited to black women.
In our study, the median length of follow-up since breast
cancer diagnosis was 10.2 years; this is longer than the me-
dian length of follow-up in many prior breast cancer-
related lymphedema studies. With this extended follow-up
time, we were able to capture a substantial number of cases
of late-onset lymphedema, which allowed us to compare
risk factors between early- and late-onset lymphedema.
Moreover, unlike many previous studies, this study con-
sisted of a large, multiethnic sample of breast cancer survi-
vors drawn from population-based cancer registries. This
diverse population allowed us to study associations within
groups defined by race and ethnicity and identify potential
heterogeneity across race and ethnicity. However, this
study has several limitations, which should be considered
when interpreting the results. This study consisted of
women who were diagnosed between 1995 and 1999 when
sentinel lymph node biopsy was less common. According
to Chen et al. [46], the use of sentinel lymph node biopsy
increased from 26.8% in 1998 to 65.5% in 2005 among
early-stage breast cancer patients. Given the risk of lymph-
edema is smaller when sentinel lymph node biopsy is used
instead of axillary lymph node dissection, our estimate of
lymphedema incidence may be greater than the incidence
observed in more recent years. Furthermore, the selection
of chemotherapeutic agents has expanded over the years,
possibly limiting the application of results to more recent
regimens. In our study, lymphedema was reported at two
time points and women indicated the approximate date
when they first experienced lymphedema, but we did not
routinely monitor the status of lymphedema over the
follow-up period. Furthermore, this study relied solely on
self-report to define existence of lymphedema and the self-
report was not verified using medical records. However,
both sensitivity and specificity of self-reported lymph-
edema were found to be high in a previous study [47], and
our results are largely consistent with those from studies
where objective measurements of lymphedema were used.
Our results were consistent with those showing associa-
tions of axillary lymph node excision [16,25,31], greater
BMI [27,30,31], and extensive surgery [16,30,31] with in-
creased risk of lymphedema, while the prior associations of
age [16,25-27,30,31], radiotherapy [25-27], and chemother-
apy [16,25-27] with lymphedema were somewhat inconsist-
ent with our data. Inconsistent findings across studies
could be explained by differences in demographic and
tumor characteristics, or variations in length of follow-up.
We were also limited by insufficient statistical power tostudy three-way interactions; for example, we were unable
to determine how race/ethnicity, chemotherapy, and
hypertension interact in relation to lymphedema risk.
Conclusions
Our multiethnic cohort study confirms that lymphedema
incidence is highest in the first year following breast
cancer diagnosis, but also indicates that approximately
45% of women who developed lymphedema first experi-
enced the condition more than one year after initial
diagnosis. Furthermore, it shows that the majority of
lymphedema cases persist for a long time. It is important
to pay closer attention to women who had extensive
lymph node dissection, had more extensive surgery, or
were obese prior to diagnosis in order to detect lymph-
edema and provide education and treatment to manage
lymphedema at an early stage. More data from multieth-
nic cohort studies are needed to confirm our finding
that hypertension and chemotherapy are risk factors
only among black women. Clinical trials are needed to
determine whether treatment for hypertension and obes-
ity might prevent the incidence or severity of lymph-
edema in breast cancer survivors.
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